Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer.

Journal of Nanobiotechnology
Peiqi ZhaoHuilai Zhang

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive malignant disease with a high rate of recurrence and metastasis, few effective treatment options and poor prognosis. Here, we designed and constructed a combined photothermal immunotherapy strategy based on cancer cell membrane-coated biomimetic black phosphorus quantum dots (BBPQDs) for tumor-targeted photothermal therapy and anti-PD-L1 mediated immunotherapy. BBPQDs have good photothermal conversion efficiency and can efficiently target tumor cells through homologous targeting and tumor homing. Under near infrared irradiation, we found that BBPQDs kill tumors directly through photothermal effects and induce dendritic cells maturation. In vivo studies have confirmed that the combined photothermal immunotherapy strategy displays a stronger antitumor activity than anti-PD-L1 monotherapy. In addition, BBPQDs-mediated photothermal therapy in combination with anti-PD-L1 treatment inhibit tumor recurrence and metastasis by reprograming the immunosuppressive tumor microenvironment into an immune-active microenvironment, and promoting the local and systemic antitumor immune response. We further found that the combined photothermal immunotherapy strategy can produce an immune ...Continue Reading

References

Jan 28, 1994·Cell·C A Janeway, K Bottomly
Jul 5, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Warren N D'Souza, Stephen M Hedrick
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Dec 5, 2008·Accounts of Chemical Research·Surbhi LalNaomi J Halas
Apr 16, 2009·Cancer Research·Geoffrey von MaltzahnSangeeta N Bhatia
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S J DawsonC Caldas
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Nov 16, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Peijian SunZhihua Gan
Feb 10, 2011·The Oncologist·Clifford A Hudis, Luca Gianni
Aug 19, 2011·Accounts of Chemical Research·Marites P MelanconChun Li
Oct 12, 2013·CA: a Cancer Journal for Clinicians·Avnesh S Thakor, Sanjiv S Gambhir
Feb 25, 2015·Nature Communications·Ichiko KinjyoWolfgang Weninger
Oct 30, 2015·CA: a Cancer Journal for Clinicians·Carol E DeSantisAhmedin Jemal
Dec 18, 2015·BBA Clinical·Elma A O'ReillyAmanda McCann
Mar 13, 2016·Advanced Materials·Lang RaoXing-Zhong Zhao
May 4, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rita NandaLaurence Buisseret
Feb 8, 2018·Translational Oncology·Zhixian LiuXiaosheng Wang
Mar 10, 2018·Materials Science & Engineering. C, Materials for Biological Applications·Peiqi ZhaoHuilai Zhang
May 13, 2018·BMC Cancer·Joshua P BatesTonya J Webb
Nov 27, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S AdamsJ Cortés
Jan 9, 2020·Accounts of Chemical Research·Li-Li HuangHai-Yan Xie
Jun 10, 2020·ACS Applied Materials & Interfaces·Haitao SunHangrong Chen
Sep 6, 2020·The Lancet Oncology·María Ochoa de OlzaGeorge Coukos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.